Methods of using deacetylase inhibitors to promote cell...

Details Methods of using deacetylase inhibitors to promote cell... Methods of using deacetylase inhibitors to promote cell...

2007-06-12

2007-06-12

Henley, III, Raymond J. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C514S574000, C514S619000

Reexamination Certificate

active

10492901

ABSTRACT:
A method of enhancing progenitor cell differentiation, including enhancing myogenesis, neurogenesis, and hematopoiesis, by contacting a progenitor cell with an effective amount of a deacetylase inhibitor (DI). The progenitor cell can be part of cell culture, such as a cell culture used for in vitro or in vivo analysis of progenitor cell differentiation, or can be part of an organsism, such as a human or other mammal. Contacting the progenitor cell with a DI can lead to enhancement of expression of terminal cell-type specific genes in the progenitor cell, such as enhancing expression of muscle-specific genes in myoblasts. Administering a DI to a subject also can provide some prophylactic or therapeutic effect for inhibiting, preventing, or treating associated with a degeneration or loss of tissue. The DI can be administered to a subject as part of a pharmaceutical composition.

REFERENCES:
patent: 4443470 (1984-04-01), Hodge et al.
patent: 4822821 (1989-04-01), Perrine
patent: 5025029 (1991-06-01), Perrine
patent: 5185436 (1993-02-01), Villa et al.
patent: 5563173 (1996-10-01), Yatsu et al.
patent: 5834249 (1998-11-01), Furukawa et al.
patent: 5993845 (1999-11-01), Geerts et al.
patent: 6030961 (2000-02-01), Nudelman et al.
patent: 6043389 (2000-03-01), Nudelman et al.
patent: 6110697 (2000-08-01), Dulski et al.
patent: 2002/0183388 (2002-12-01), Gudas
patent: 0 424 055 (1994-12-01), None
patent: 0 827 742 (1998-03-01), None
patent: WO 96/39035 (1996-12-01), None
patent: WO 99/23885 (1999-05-01), None
patent: WO 99/37150 (1999-07-01), None
patent: WO 00/06720 (2000-02-01), None
patent: WO 00/08048 (2000-02-01), None
patent: WO 01/18171 (2001-03-01), None
McCaffrey et al., 1997, Blood, 90: 2075-2083.
Davis et al., “Histone Deacetylase Inhibitors Decrease Proliferation and Modulate Cell Cycle Gene Expression in Normal Mammary Epithelial Cells.”Clinical Cancer Research, 6(11):4334-4342, Nov. 2000.
Steinbach et al., “Histone Deacetylase Activity Is Required for the Induction of the MyoD Muscle Cell Lineage inXenopus,” Biological Chemistry, 381(9-10):1013-1016, Sep./Oct. 2000.
Gabbianelli et al., “Hemoglobin switching in unicellular erythroid culture of sibling erythroid burst-forming units: kit ligand induces a dose-dependent fetal hemoglobin reactivation potentiated by sodium butyrate,”Blood, 95(11):3555-3561, Jun. 2000.
O'Neil et al., “A developmental switch in H4 acetylation upstream ofXistplays a role in X chromosome inactivation.”EMBO Journal, 18(10):2897-2907, 1999.
Schultz et al., “Reprogramming of Gene Expression During Preimplantation Development.”Journal of Experimental Zoology, 285(3):276-282, Oct. 1999.
Blau and Epstein, “Manipulation of Myogenesis in Vitro: Reversible Inhibition by DMSO,”Cell, 17(1):95-108, 1979.
Johnston et al., “Sodium Butyrate Inhibits Myogenesis by Interfering with the Transcriptional Activation Function of MyoD and Myogenin,”Mol. Cell. Biol., 12(11)5123-5130, 1992.
Fiszman et al., “Expression of Myogenic Differentiation and Myotube Formation by Chick Embryo Myoblasts in the Presence of Sodium Butyrate,”Exp. Cell Res., 126:31-37, 1980.
Mal et al., “A Role of Histone Deacetylase HDAC1 in Modulating the Transcriptional Activity of MyoD: Inhibition of the Myogenic Program,”EMBO J., 20(7): 1739-1753, 2001.
Richon et al., “Histone Deacetylase Inhibitor Selectively Induces p21WAFIExpression and Gene-Associated Histone Acetylation,”Proc. Natl. Acad. Sci. USA, 97(18):10014-10019, 2000.
Sartorelli et al., “Acetylation of MyoD Directed by PCAF Is Necessary for the Execution of the Muscle Program,”Mol. Cell, 4:725-734, 1999.
Zhang et al., “The Transcriptional Corepressor MITR is a Signal-Responsive Inhibitor of Myogenesis,”Proc. Natl. Acad. Sci. USA, 98(13):7354-7359, 2001.
Zhao et al., “The Modular Nature of Histone Deacetylase hdac4 Confers Phosphorylation-Dependent Intracellular Trafficking,”J. Biol. Chem., 276(37):35042-35048, 2001.
Choi et al., “14-3-3tau Associates with and Acivates the MEF2D Transcription Factor During Muscle Cell Differentiation,”Nucleic Acids Res., 29(13):2836-2842, 2001 (abstract only).
Lu et al., “Regulation of Skeletal Myogenesis by Association of the MEF2 Transcription Factor with Class II Histone Deacetylases,”Mol. Cell, 6(2):233-244, 2000 (abstract only).
Youn et al., “Calcium Regulates Transcriptional Repression of Myocyte Enhancer Factor 2 by Histone Deacetylase 4,”J. Biol. Chem., 275(29):22563-22567, 2000 (abstract only).
Iezzi et al., “Deacetylase Inhibitors Increase Muscle Cell Size by Promoting Myoblast Recruitment and Fusion through Induction of Follistatin,”Developmental Cell, 6:673-684, 2004.

Affiliated with

Also associated with

Rating

Methods of using deacetylase inhibitors to promote cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of using deacetylase inhibitors to promote cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using deacetylase inhibitors to promote cell... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3871416